Immunodeficient rodents

Explore our immunodeficient models, featuring cutting-edge strains like BRGSF mouse and SDRG rat.

‍

Applications

Our immunodeficient models are valuable tools in a wide range of biomedical fields, including oncology, immunology and infectious diseases. Their compromised immune systems allow the engraftment of human tissues, cells (such as human hematopoietic cells) or tumors, making them ideal models for evaluating human immune responses, disease progression and therapeutic interventions. The genetic modifications in our immunodeficient models are designed to reduce the number of murine immune cells while making them more robust and predictable than SCID models.

General model features

Absence of lymphoid cells
Extended lifespan, enabling long-term studies
Robust models with high tolerance to tumor engraftment

Discover our

Immunodeficient rodents

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Btk rat

Btk Knockout rat to study B-cell malignancies, aberrant B-cell responses, Btk inhibitors for treatments of hematologic cancers or autoimmune diseases.

BTK

Immunodeficient

KO-Rep-Mix

BRGSF

Compared to NOD-SCID and NSG, the BRGSF mouse represents the most adapted animal model to study and predict human immune responses in vivo.

BRGSF

Immunodeficient

SDRG

The immunodeficient SDRG rat model is a double Knockout for Rag1 and IL-2Rγ genes (Rag1^-/- Il2rγ^-/-), resulting in a B, T, and NK cell deficiency.

SDRG

Immunodeficient

Discover our customized models

Related resources and publications

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

pain research

nutrition

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Assessment of γδ T-cell therapies in humanized mice

BRGSF-HIS for γδ T-cell therapies

Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice

TME composition in BRGSF-HIS mice

BRGSF-HIS mice as a predictive tool for safety assessment of biologics

BRGSF-HIS for safety assessment

(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy

In vivo tumor growth suppression

Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice

BRGSF-HIS & tumor microenvironment

Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

BRGSF-HIS & myeloid cell compartment in CRS

Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment

BRGSF-HIS for myeloid-directed therapy assessment

CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

Efficient generation of human immune system rats using human CD34+ cells

Stem Cell Reports

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Nat Commun

Highlighted article

read the comment

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

Front Immunol

Highlighted article

read the comment

Staphylococcus aureus Panton-Valentine Leukocidin worsens acute implant-associated osteomyelitis in humanized BRGSF mice

JBMRplus

Highlighted article

read the comment

Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity

PLoS One

Frontline Science: Exhaustion and senescence marker profiles on human T cells in BRGSF‐A2 humanized mice resemble those in human samples

J Leukoc Biol

Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

Immuno-oncolology models

Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Immuno-oncolology models

BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

No results

Other categories

Humanized mice (HIS/human immune system)

Address human-specific questions in a more relevant manner, facilitating translational research in several biomedical disciplines and approaches.

Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.

Knockout and reporter models

Our off-the-shelf Knockout & reporter models are well established, validated and widely used mouse and rat lines.

Cell lines

Our humanized & Knockout ICP cell lines can be used for in vivo tumor growth assays in syngeneic models and in vitro mechanistic studies.